Recent Articles
in CANCER GENOMICS & PROTEOMICS 2013

(available online – open access at http://cgp.iiarjournals.org)


- **Association of p21, p21 p27 and p21 p53 Status to Histological Subtypes and Prognosis in Low-stage Epithelial Ovarian Cancer. I. SKIRNISDOTTIR, T. SEIDAL (Uppsala; Halmstad, Sweden)

- **Identification by High-throughput In Silico Screening of Radio-protecting Compounds Targeting the DNA-binding Domain of the Tumor Suppressor p53. T. EICHHORN, C. HILLER, K. HIRSCHFELDER, M. FRANK, R.L. KRAUTH-SIEGEL, R. MÜLLER, R. MERTENS, T. EFFERTH (Mainz; Heidelberg; Saarbrücken; Aachen, Germany)

- **The Differential Expression of Vascular Endothelial Growth Inhibitor Isoforms, VEGI251, VEGI174 and VEGI192 in Human Clear-cell Renal Cell Carcinoma. N. ZHANG, P. WU, L. WU, D. SHAYIREMU, H. SHAN, L. YE, W.G. JIANG, K. GONG, Y. YANG (Beijing; Hami, Xinjiang, PR, China; Cardiff, UK)

- **Clinicopathological Correlation and Prognostic Significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 Expression in Colorectal Cancer. S.F. MARTINS, E.A. GARCIA, M.A.M. LUZ, F. PARDAL, M. RODRIGUES, A.L. FILHO (Braga; Guimarães; Vila Real, Portugal; São Paulo, Brazil)

- **Guanine Nucleotide Binding Protein β 1: A Novel Transduction Protein with a Possible Role in Human Breast Cancer. U. WAZIR, W.G. JIANG, A.K. SHARMA, K. MOKBEL (London; Cardiff, Wales, UK)


- **Dihydropyrimidine Dehydrogenase Gene (DPYD) Polymorphism among Caucasian and non-Caucasian Patients with 5-FU- and Capecitabine-related Toxicity Using Full Sequencing of DPYD. M.W. SAIF (Boston, MA, USA)


- **Proteomic Analysis of Normal Murine Brain Parts. V.K. TARASLIA, A. KOUSKOUKIS, A.K. ANAGNOSTOPOULOS, D.J. STRAVOPODIS, L.H. MARGARITIS, G.TH. TSANGARIS (Athens, Greece)

- **Review**: The Role of Thiamine in Cancer: Possible Genetic and Cellular Signaling Mechanisms. K. VINH Q. LƯƠNG, L.T. NGUYỄN (Westminster, CA, USA)

- **A Role for WISP2 in Colorectal Cancer Cell Invasion and Motility K.A. FREWER, A.J. SANDERS, S. OWEN, N.C. FREWER, R. HARGEST, W.G. JIANG (Cardiff, UK)
Instructions to Authors 2013

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer; and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

**Nomenclature and Abbreviations.** Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey’s Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (http://www.gene.ucl.ac.uk/). Approved mouse nomenclature may be obtained from http://www.informatics.jax.org/. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

**Ethical Policies and Standards.** ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice):

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delasios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH, IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2013 - International Institute of Anticancer Research (J.G. Delasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
A Selection of Recent Papers

Metastatic Biomarker Discovery Through Proteomics. L.T. BRINTON, T.A. BRENTNALL, J.A. SMITH, K.A. KELLY (Charlottesville, VA; Seattle, WA, USA)


Review: Breast Cancer and Metastasis: On the Way Toward Individualized Therapy. A.P. TRAPÊ, A.M. GONZALEZ-ANGULO (Houston, TX, USA)

In Silico Functional Profiling of Individual Prostate Cancer Tumors: Many Genes, Few Functions. I.P. GORLOV, J. BYUN, C.J. LOGOTHETIS (Houston, TX, USA)

Expression of Signal-induced Proliferation-associated Gene 1 (SIPA1), a RapGTPase-activating Protein, Is Increased in Colorectal Cancer and Has Diverse Effects on Functions of Colorectal Cancer Cells. K. JI, L. YE, A.-M. TOMS, R. HARGEST, T.A. MARTIN, F. RUGE, J. JI, W.G. JIANG (Cardiff, UK; Beijing, PR China)

Single Nucleotide Polymorphisms of Genes for EGF, TGF-β and TNF-α in Patients with Pancreatic Carcinoma. L. ZHANG, G. WU, F. HERRLE, M. NIEDERGETHMANN, M. KEESE (Frankfurt; Heidelberg, Germany; Xiamen, P.R. China)

Diagnostic MicroRNA Markers to Screen for Sporadic Human Colon Cancer in Blood. F.E. AHMED, N.C. AMED, P.W. VOS, C. BONNERUP, J.N. ATKINS, M. CASEY, G.J. NUOVO, W. NAZIRI, J.E. WILEY, R.R. ALLISON (Greenville, Goldsboro, NC; Columbus, OH, USA)

MGMT Hypermethylation and MDR System in Glioblastoma Cancer Stem Cells. V. CALDERA, M. MELLAI, L. ANNOVAZZI, O. MONZEGLIO, A. PIAZZI, D. SCHIFFER (Pavia; Novara, Italy)

20-HETE-producing Enzymes Are Up-regulated in Human Cancers. A. ALEXANIAN, B. MILLER, R.J. ROMAN, A. SOROKIN (Milwaukee, WI; Jackson, MS, USA)

Unifying the Genomics-based Classes of Cancer Fusion Gene Partners: Large Cancer Fusion Genes are Evolutionarily Conserved. L.M. PAVA, D.T. MORTON, R. CHEN, G. BLANCK (Tampa, FL, USA)
Cessation of Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myelogenous Leukemia Following Durable Complete Molecular Response: A Single Center Facing the Dilemma. T. Iliakis, V. Papadopoulos, P.T. Diamantopoulos, P. Panayiotidis, K. Zervakis, N. Giannakopoulos, G. Tilimidos, M. Angelopoulos, M.P. SiaKatariis, G. Pangalis, M. Mantzourani, E. Variami, N.A. Viniou (Athens, Greece) ................................................................. 3509

Intrathecal Liposomal Cytarabine and Leptomeningeal Medulloblastoma Relapse: A Valuable Therapeutic Option. A. Mastronucci, F. Del Bufalo, A. Iacono, D.E. Secco, A. Serra, G.S. Colafati, M.A. De Ioris, T. Corsetti (Rome, Italy) ................................................................. 3515

Errata ................................................................................................................................. 3519

Book Reviews .................................................................................................................... 3521
Reduction in γ-Glutamyl Hydrolase Expression Is Associated with Response to Uracil and Tegafur/Leucovorin Chemotherapy in Patients with Colorectal Cancer. S. SADAHIRO, T. SUZUKI, A. TANAKA, K. OKADA, A. KAMIJO, H. NAGASE, J. UCHIDA (Kanagawa; Tokushima, Japan) ........ 3431

High Efficacy of Chemoradiation Therapy Sensitized by Weekly Docetaxel for Anaplastic Thyroid Cancer. N. ONODA, S. KASHIWAGI, S. NODA, H. KAWAJIRI, T. TAKASHIMA, T. ISHIKAWA, K. HIRAKAWA (Osaka, Japan) ........ 3439

Comparison Between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as Palliative First-line Chemotherapy for Adenocarcinoma of the Upper Gastrointestinal Tract. A. ILHAN-MUTLU, M. PREUSSER, S.F. SCHOPPMANN, R. ASARI, A. BASSALAMAH, K. SCHWAMEIS, U. PLUSCHNIG, P. BIRNER, A. PÜSPÖK, J. ZACHERL, M. HEJNA (Vienna, Austria) .................. 3455


Prolonged Administration of Adjuvant Temozolomide Improves Survival in Adult Patients with Glioblastoma. A. DARLIX, C. BAUMANN, V. LORGIS, F. GHIRINGHELLI, M. BLONSKI, B. CHAUFFERT, S. ZOUAOU, C. PINELLI, F. RECH, P. BEAUCHESNE, L. TAILLANDIER (Nancy; Dijon; Amiens; Montpellier, France) .... 3467

Overexpression of Survivin Levels in Circulation and Tissue Samples of Lung Cancer Patients. G. KAPELLOS, K. POLONIFI, D. FARMAKIS, E. SPARTALIS, P. TOMOS, A. AESOPOPOUS, A. POLIZOS, M. MANTZOURANI (Athens, Greece) ................................................................. 3475

HPV Status and Overall Survival of Patients with Oropharyngeal Squamous Cell Carcinoma – A Retrospective Study of a German Head and Neck Cancer Center. A. TAHTALI, C. HEY, C. GEISSLER, N. FILMAN, M. DIENSTHUBER, M. LEINUNG, T. STÖVER, J. WAGENBLAST (Frankfurt am Main, Germany) ........... 3481

Sorafenib plus Daily Low-dose Temozolomide for Relapsed Glioblastoma: A Phase II Study. F. ZUSTOVICH, L. LANDI, G. LOMBARDI, C. PORTA, L. GALLI, A. FONTANA, D. AMOROSO, C. GALLI, M. ANDREUCCETTI, A. FALCONE, V. ZAGONEL (Padova; Livorno; Pavia; Pisa; Viareggio; Firenze, Italy) ................................................................. 3487

Treatment Outcomes and Prognostic Factors for Thoracic Esophageal Cancer with Clinical Evidence of Adjacent Organ Invasion. Y. HAMAI, J. HIHARA, M. EMI, J. TAOMOTO, Y. AOKI, I. KISHIMOTO, Y. IBUKI, M. OKADA (Hiroshima, Japan) ................................................................. 3495

Two Different Hypofractionated Breast Radiotherapy Schedules for 113 Patients with Ductal Carcinoma In Situ: Preliminary Results. M. GUENZI, F. GIANNELLI, D. BOSETTI, G. BLANDINO, M.L. MILANESE, F. PUPILLO, R. CORVÒ, A. FOZZA (Genoa, Italy) ................................................................. 3503

Contents continued on the preceding page


Beta-2 Microglobulin as a Diagnostic Parameter in Non-Hodgkin Lymphoma: A Comparative Study with FDG-PET. D.F. TOOTH, M. RADERER, W. WADSAK, G. KARANIKAS (Vienna, Austria) ......................... 3341

Predictability of Oral and Laryngopharyngeal Function for Aspiration and Limitation of Oral Intake in Patients After Surgery for Head and Neck Cancer. C. HEY, B.P. LANGE, C. AERE, S. EBERLE, Y. ZARETSKY, R. SADER, T. STÖVER, J. WAGENBLAST (Frankfurt/Main; Göttingen, Germany) ................................. 3347


Intragastric SILS for GIST, a New Challenge in Oncologic Surgery: First Experiences. K. DE VOGELAERE, N. VAN DE WINKEL, C. SIMOENS, G. DELVAUX (Brussels, Belgium) ................................................................. 3359

Nevus of Hoffmann-Zurhelle: A Case Around the Right Parotid Duct. F. ANGIERO, R. CRIPPA (Genoa, Italy) ................................................................................................................................. 3365

Investigation of FANCA Mutations in Greek Patients. N. SELENTI, C. SOFOCLEOUS, A. KATTAMIS, A. KOLIALEXI, S. KITSIOU, E. FRYSSIRA, S. POLYCHRONOPOULOU, E. KANAVAKIS, A. MAVROU (Athens, Greece) ................................................................. 3369

Survey among German Gynecologists on the Clinical Management of Patients with Sarcomas of the Uterus. F.C.-K. CHEN, M. DAVID, R. RICHTER, M.Z. MUALLEM, R. CHEKEROV, J. SEHOULI (Berlin, Germany) ................................................................................................................................. 3375

Continuous Tamoxifen and Dose-dense Temozolomide in Recurrent Glioblastoma. A. DI CRISTOFORI, G. CARRABBA, G. LANFRANCHI, C. MENGHETTI, P. RAMPINI, M. CAROLI (Milan, Italy) ......................... 3383

Association of Interleukin-10 (IL10) Promoter Genotypes with Nasopharyngeal Carcinoma Risk in Taiwan. C.-W. TSAI, M.-H. TSAI, L.-C. SHIH, W.-S. CHANG, C.-C. LIN, D.-T. BAU (Taichung, Taiwan, ROC) ............. 3391

Sequential Treatment of Advanced-stage Lung Adenocarcinoma Harboring Wild-type EGFR Gene: Second-line Pemetrexed Followed by Third-line Erlotinib versus the Reverse Sequence. Ő. FIALA, M. PESEK, J. FINEK, L. BENSEDOVA, Z. BORTLICEK, M. MINARIK (Pilsen; Prague; Brno, Czech Republic) ......................... 3397

Whole-body versus Segmental Bioelectrical Impedance Analysis in Patients with Edema of the Upper Limb After Breast Cancer Treatment. S. BERLIT, J. BRADE, B. TUSCHY, E. FÖLDI, U. WALZ-ESCHENLOHR, H. LEWELING, M. SÜTTERLIN (Mannheim; Hinterzarten, Germany) ................................................................................................................................. 3403

Nab-Paclitaxel Monotherapy as a Treatment of Patients with Metastatic Breast Cancer in Routine Clinical Practice. J. AIGNER, F. MARMÉ, K. SMETANAY, F. SCHUETZ, D. JAEGGER, A. SCHNEEWEISS (Heidelberg, Germany) ................................................................................................................................. 3407

Relationship between Cancer-related Fatigue and Physical Activity in Inpatient Cancer Rehabilitation. F. KUMMER, S. CATUOGNO, J.M. PERSEUS, W. BLOCH, F.T. BAUMANN (Cologne, Germany; Davos, Switzerland) ................................................................................................................................. 3415

Contents continued on the preceding page
Clinical Studies


Gene Polymorphism of Matrix Metalloproteinase-12 and -13 and Association with Colorectal Cancer in Swedish Patients. S. VAN NGUYEN, M. SKARSTEDT, S. LÖFGREN, N. ZAR, R.E. ANDERSSON, M. LINDH, A. MATUSSEK, J. DIMBERG (Da Nang, Vietnam; Jönköping Sweden) ........................................

Primary Central Nervous System Lymphoma in the Elderly: The Cleveland Clinic Experience. H. XIE, S. DAHIYA, E.S. MURPHY, S.T. CHAO, J.H. SUH, G.H.J. STEVENS, D.M. PEEREBOOM, M.S. AHLUWALIA (Cleveland, OH, USA) .................................................................

Collagenous Fibroma (Desmoplastic Fibroblastoma) with Trisomy 8 as the Sole Cytogenetic Abnormality. J. NISHIO, H. IWASAKI, S. YANO, M. NAITO (Fukuoka, Japan) .................................................................

Fatal Herpes Encephalitis in a Patient with Small Cell Lung Cancer Following Prophylactic Cranial Radiation - A Case Report with Review of Literature. S. CHAKRABORTY, M. DONNER, D. COLAN (Omaha; Grand Island, NE, USA) .................................................................................................................................

Laparoscopic Minimally Invasive Total Gastrectomy with Linear Stapled Oesophagojejunostomy – Experience from the First Thirty Procedures. T.I. PETERSEN, E. PAHLE, T. SOMMER, T. ZILLING (Aarhus, Denmark) ........................................

Platinum-based Doublet Chemotherapy plus Bevacizumab Without Bevacizumab Maintenance in Advanced Non-small Cell Lung Cancer (NSCLC). D.S. NØRØXE, S. WALLEREK, J.B. SØRENSEN (Copenhagen, Denmark) .................................................................................................................................


Outpatient Oral Chemotherapy with S-1 for Unresectable or Distant Metastatic Head and Neck Cancer. M. MAEDA, T. YAMASHITA, T. MATSUNOBU, K. ARAKI, M. TOMIFUJI, A. SHIOTANI (Saitama, Japan) .................................................................................................................................

A High Preoperative Neutrophil–to–lymphocyte Ratio Is Associated with Poor Survival in Patients with Colorectal Cancer. M. SHIBUTANI, K. MAEDA, H. NAGAHARA, E. NODA, H. OHTANI, Y. NISHIGUCHI, K. HIRAKAWA (Osaka, Japan) .................................................................................................................................

Increased Phosphorylation of AKT in High-risk Gastric Mucosa. T. SASAKI, H. KUNIYASU, Y. LUO, M. KITAYOSHI, E. TANABE, D. KATO, S. SHINYA, K. FUJI, H. OHMORI, Y. YAMASHITA (Fukuoka; Kashihara, Japan) .................................................................................................................................

Low Expression of Claudin-1 and Presence of Poorly- differentiated Tumor Clusters Correlate with Poor Prognosis in Colorectal Cancer. M. SHIBUTANI, E. NODA, K. MAEDA, H. NAGAHARA, H. OHTANI, K. HIRAKAWA (Osaka, Japan) .................................................................................................................................

Etoposide Improves Survival in High-grade Glioma: A Meta-Analysis. A. LEONARD, J.E. WOLFF (Boston, MA, USA) .................................................................................................................................

Efficacy of Postoperative Oxaliplatin- or Irinotecan-based Chemotherapy After Curative Resection of Synchronous Liver Metastases from Colorectal Cancer. H.-C. HSU, W.-C. CHOU, W.-C. SHEN, C.-E. WU, J.-S. CHEN, C.-T. LIAU, Y.-C. LIN, T.-S. YANG (Tao-Yuan, Taiwan, ROC) .................................................................................................................................
Up-regulation of DDX39 in Human Pancreatic Cancer Cells with Acquired Gemcitabine Resistance Compared to Gemcitabine-sensitive Parental Cells. Y. KURAMITSU, S. SUENAGA, Y. WANG, K. TOKUDA, T. KITAGAWA, T. TANAKA, J. AKADA, S.-I. MAEHARA, Y. MAEHARA, K. NAKAMURA (Ube, Yamaguchi; Fukuoka, Japan) ................................................................. 3133

High Cyclooxygenase-2 Expression Is Associated with Advanced Stages in Colorectal Cancer. A. ELZAGHEID, F. EMAETIG, L. ALKIKHIA, A. BUHMEIDA, K. SYRJÄNEN, O. EL-FAITORI, M. LATTO, Y. COLLAN, S. PYRHÖNEN (Benghazi; Tripoli, Libya; Jeddah, Saudi Arabia; Turku, Finland; Barretos, SP, Brazil) ................................................................. 3137

Sonodynamically-induced Anticancer Effects by Functionalized Fullerenes. N. YUMITA, Y. IWASE, T. IMAIZUMI, A. SAKURAZAWA, Y. KAYA, K. NISHI, T. IKEDA, S.-I. UMEMURA, F.-S. CHEN, Y. MOMOSE (Yokohama, Kanagawa; Sendai; Funabashi, Chiba, Japan; Hualien, Taiwan, ROC) ................................................................. 3145

Curcumin Reduces Trabecular and Cortical Bone in Naïve and Lewis Lung Carcinoma-bearing Mice. L. YAN, J.A. YEE, J. CAO (Grand Forks, ND; Omaha, NE, USA) ................................................................. 3153

9-Norbornyl-6-chloropurine Is a Novel Antileukemic Compound Interacting with Cellular GSH. P. PLAČKOVÁ, N. ROZUMOVÁ, H. HŘEBABECKÝ, M. ŠÁLA, R. NENCKA, T. ELBERT, A. DVORÁKOVÁ, I. VOTRUBA, H. MERTLÍKOVÁ-KAISEROVÁ (Prague, Czech Republic) ................................................................. 3163

Proliferation of Small Cell Lung Cancer Cell Line Reduced by Knocking-down PROX1 via shRNA in Lentivirus. S.-H. ZHU, C.-J. SHAN, Z.-F. WU, S.-Z. XU (Jiangsu, PR China; Rochester, MN, USA) ................................................................. 3169


Evaluation of MicroRNA Expression Pattern of Gastric Adenocarcinoma Associated with Socioeconomic, Environmental and Lifestyle Factors in Northwestern Hungary. I. STÁNITZ, K. JUHÁSZ, C. TÓTH, K. GOMBOS, P.G. NATALI, I. EMBER (Pécs; Szombathely, Hungary; Rome, Italy) ................................................................. 3195

Cell Harvesting Method Influences Results of Apoptosis Analysis by Annexin V Staining. A. BUNDSCHERER, M. MALSÝ, R. LANGE, P. HOFMANN, T. METTERLEIN, B.M. GRAF, M. GRÜBER (Regensburg, Germany) ................................................................. 3201

Parthenolide Complements the Cell Death-inducing Activity of Doxorubicin in Melanoma Cells. M. WOZNIAK, A. SZULAWSKA-MROCZEK, M.L. HARTMAN, D. NEJC, M. CZYZ (Lodz, Poland) ................................................................. 3205


Effects of Bisphosphonates in Combination with Ionizing Radiation and Antioxidants on the Growth of Prostate and Melanoma Cells Lines. M. ALCARAZ, A. OLIVARES, D.G. ACHEL, M. ALCARAZ-SAURA (Murcia, Spain; Legon-Accra, Ghana) ................................................................. 3217

15,16-Dihydrotanshinone I-induced Apoptosis in Human Colorectal Cancer Cells: Involvement of ATF3. F.-M. SUK, W.-J. JOU, R.-J. LIN, S.-Y. LIN, F.-Y. TZENG, Y.-C. LIANG (Taipei, Taiwan, ROC) ................................................................. 3225

A miR-146a Polymorphism (rs2910164) Predicts Risk of and Survival from Colorectal Cancer. Y.S. CHAE, J.G. KIM, S.J. LEE, B.W. KANG, Y.J. LEE, J.Y. PARK, H.-S. JEON, J.S. PARK, G.S. CHOI (Daegu, Republic of Korea) ................................................................. 3233

Contents continued on the preceding page
Antiproliferative and Erythroid Differentiation of Piperazine and Triphenyl Derivatives Against K-562 Human Chronic Myelogenous Leukemia. A.M. SAAB, M. DOBMEIER, B. KOENIG, E. FABRI, A. FINOTTI, M. BORGATTI, I. LAMPRONTI, F. BERNARDI, T. EFFERTH, R. GAMBARI (Ferrara, Italy; Beirut, Lebanon; Regensburg; Mainz, Germany) ................................................................. 3027

Combination Chemoprevention with Diclofenac, Calcipotriol and Difluoromethylornithine Inhibits Development of Non-melanoma Skin Cancer in Mice. H.-C. POMMERGAARD, J. BURCHARTH, J. ROSENBERG, H. RASKOV (Copenhagen; Frederiksberg, Denmark) ........................................... 3033

Color-coded Imaging of Spontaneous Vessel Anastomosis In Vivo. F. UEHARA, Y. TOME, J. REYNOSO, S. MII, S. YANO, S. MIWA, M. BOUVET, H. MAEHARA, F. KANAYA, A.R. MOOSSA, R.M. HOFFMAN (San Diego, CA, USA; Okinawa, Japan) .......................................................... 3041

Nicotinamide Phosphoribosyltransferase and SIRT3 Expression Are Increased in Well-differentiated Thyroid Carcinomas. R. SHACKELFORD, S. HIRSH, K. HENRY, A. ABDEL-MAGEED, E. KANDIL, D. COPPOLA (New Orleans; Gretna, LA; Tampa, FL, USA) ............................................. 3047

The Growing Galectin Network in Colon Cancer and Clinical Relevance of Cytoplasmic Galectin-3 Reactivity. H. DAWSON, S. ANDRÉ, E. KARAMITOPoulos, I. ZLOBEC, H.-J. GABIUS (Bern, Switzerland; Munich, Germany) ........................................................................ 3053

Evaluation of Cytotoxicity and Tumor-specificity of Licorice Flavonoids Based on Chemical Structure. H. OHNO, D. ARAHO, Y. UESAWA, H. KAGAYA, M. ISHIHARA, H. SAKAGAMI, M. YAMAMOTO (Shibuya; Kiyose, Tokyo; Sakado, Saitama, Japan) ................................................................. 3061

HMGA2 Expression in the PC-3 Prostate Cancer Cell Line Is Autonomous of Growth Factor Stimulation. M.H. MÜLLER, N. DRIESCHNER, T. FOCKEN, S. BARTNITZKE, N. WINTER, M. KLEMKE, J. BULLERDIEK (Bremen, Germany) .......................................................... 3069

Effects of Artonin E on Migration and Invasion Capabilities of Human Lung Cancer Cells. K. PLAIBUA, V. PONGRAKCHANANON, P. CHUNHACHA, B. SRITULARAK, P. CHANVORACHOTE (Bangkok, Thailand) ................................................................. 3079


Effects of the HIF1 Inhibitor, Echinomycin, on Growth and NOTCH Signalling in Leukaemia Cells. S. YONEKURA, M. ITOH, Y. OKUHASHI, Y. TAKAHASHI, A. ONO, N. NARA, S. TOHDA (Tokyo, Japan) ................................................................. 3099


Keratinocytes and Head and Neck Squamous Cell Carcinoma Cells Regulate Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Fibroblasts. M. HAKELIUS, A. KOSKELA, M. IVARSSON, R. GRENNAN, K. RUBIN, B. GERDIN, D. NOWINSKI (Uppsala; Örebro, Sweden; Turku, Finland) ................................................................. 3113

The Role of p66shc in Taxol- and Dichloroacetic Acid-dependent Renal Toxicity. I ARANY, J.S. CLARK, D. REED, I. SZABÓ, I. EMBER, L.A. JUNCOS (Jackson, MS, USA; Pécs, Hungary) ................................................................. 3119

Expression of the mTOR Pathway Regulators in Human Pituitary Adenomas Indicates the Clinical Course. W. JIA, A.J. SANDERS, G. JIA, X. LIU, R. LU, W.G. JIANG (Beijing, PR China; Cardiff, UK) ................................................................. 3123